To ascertain if antidepressants, as a group, increase the risk for major malformations, as well as assessing each individual antidepressant.
S elective serotonin reuptake inhibitors (SSRIs) were developed and released on the market in the United States in 1988 and in Canada in the early 1990s with fluoxetine as the prototype. Subsequently, other classes of antidepressants have been developed and introduced, such as serotonin norepinephrine reuptake inhibitors (for example, venlafaxine), aminoketones (bupropion), phenylpiperazine (nefazodone, an updated version of trazodone that was released in the late 1970s), and noradrenergic and specific serotonin antidepressants (for example, mirtazapine).
More women than men suffer from depression with up to 20% of women of childbearing age diagnosed with the condition, most prevalent between the ages of 25 and 44 years. 1 About 10% to 15% of these women experience depression during pregnancy and in the postpartum period. 2 Therefore, a substantial number of women are likely to be taking antidepressants when they become pregnant.
Prior to late 2005, there was no evidence that the newer antidepressants, as a group, increased the incidence of major malformations above the 1% to 3% found in the general population. 3, 4 However, in 2005 and 2006, GlaxoSmithKline published on their website preliminary results of a study documenting an increased risk for cardiac malformations (2/100, compared with 1/100) in infants whose mothers took paroxetine in early pregnancy. The type of cardiac defects were not specified and some could have been minor and might have resolved spontaneously. 5 Later, they reanalyzed the data and revised the incidence to 1.5% and published the results in a peer-reviewed journal. 6 These data were supported by 2 other studies, 7, 8 where researchers also found a small increased risk for cardiovascular defects associated with only paroxetine, and not with other SSRIs. However, a recent study from Motherisk, with more than 1100 prospectively collected cases of women exposed to paroxetine in the first trimester of pregnancy, did not find an increased risk for cardiac defects. 9 In addition, in 2007, 2 case-control studies were published and in neither study was there an increased risk for most birth defects documented with the use of SSRIs in pregnancy. However, after performing numerous analyses, thereby creating a high probability of false positives owing to alpha slippage, each of those studies documented small increased risks for specific birth defects, craniosynostosis, omphalocele, or heart defects but with contradictory results. It would appear that if these drugs did cause birth defects, the same defects would have been found in both groups, and they were not. The authors did state that it should be recognized that the specific defects implicated are rare and the absolute risks are small. 10, 11 Subsequently, based on the 3 reports on paroxetine, the US Food and Drug Administration 12 and Health Canada 13 posted warnings on their websites advising women to avoid paroxetine if possible during pregnancy. In December of 2006, the American College of Obstetricians and Gynecologists published a similar advisory. 14 In addition, the National Institute for Health and Clinical Excellence guidelines from the United Kingdom stated that if a woman taking paroxetine is planning a pregnancy or has an unplanned pregnancy, she should be advised to stop taking the drug. They also stated that when choosing an antidepressant for pregnant or breastfeeding women, prescribers should, while bearing in mind that the safety of these drugs is not well understood, take into account that tricyclic antidepressants, such as amitriptyline, imipramine, and nortriptyline, have lower known risks during pregnancy than other antidepressants. 15 This last statement does not appear to be based on published evidence, as there are no studies in the peer-reviewed literature to corroborate this information.
When warnings, especially about adverse effects of exposures in pregnancy are published, they are almost always widely cited by the media and subsequently make their way to the Internet. A recent Google search, using the key words antidepressants, pregnancy, and birth defects, revealed 563 000 results, mostly describing how dangerous and harmful antidepressants are to take during pregnancy and warning women not to take them if they are pregnant. In addition, there are numerous websites that have been developed, inviting women to join a class action suit against GlaxoSmithKline if they had taken paroxetine during pregnancy and delivered a baby with a cardiovascular birth defect.
Following review of this information, much of it contradictory, it is obvious that for a physician to prescribe, and for a woman to take an antidepressant during pregnancy, it has become a complicated process. Our objective was to analyze pregnancy outcomes of women exposed to antidepressants during pregnancy in our large prospective cohort, calculate the incidence of major malformations, and compare the results with a matched comparison group.
Methods
The Motherisk Program at the Hospital for Sick Children in Toronto is a teratogenic information service. We provide evidence-based information on the safety and risks associated with exposures to drugs, chemicals, radiations, and infectious diseases during pregnancy and lactation to pregnant women, lactating mothers, and their health care providers. Women call us for information regarding the safety of a drug, usually early in pregnancy, most often following recognition of the pregnancy. During the initial telephone contact, demographics, medical, and obstetrical histories as well as details of exposure and concurrent exposures are recorded on a standardized questionnaire. Details about the exposure include duration, timing in pregnancy, dose, frequency, and indication for drug use. At the follow-up interview, gestational findings, fetal outcomes, and neonatal health are documented on a structured form by telephone interview with each mother, following a detailed explanation of the study and with her consent. The details are then, with her permission, corroborated with the report of the physician caring for the baby, which is sent out to the physicians caring for the child in question. This study protocol was approved by the Hospital for Sick Children Research Ethics Board.
We used this method to ascertain pregnancy outcomes of women who called us regarding the use of antidepressants during pregnancy and entered the details in an electronic database. We used data from women who contacted us for the antidepressant exposure and compared them with an equal number of women who were not exposed to antidepressants and who had called Motherisk for information regarding nonteratogenic drugs, such as acetaminophen. To assess the number of major malformations, we only included women who were exposed to the antidepressant during the first trimester. The 2 groups were matched for maternal age, smoking, and alcohol use. We ascertained the number of major malformations in each group in percentages and then calculated the risk ratio and 95% confidence interval between exposed and nonexposed women.
Results
We were able to analyze 928 women in each group who fulfilled the inclusion criteria. Owing to the matching, there was no difference in maternal characteristics, 20% of the women smoked and less than 1% used alcohol. The antidepressants included in the analysis were: bupropion (113), citalopram (184), escitalopram (21), fluvoxamine (52), nefazodone (49), paroxetine (148), mirtazepine (68), fluoxetine (61), trazodone (17) , venlafaxine (154), and sertraline (61).
There were 24 (2.5%) major malformations in the antidepressant group and 25 (2.6%) in the comparison group. The risk ratio was 0.96 (95% CI 0.55 to 1.67). There was no pattern of defects or clusters within any particular body system. An analysis of the malformations attributed to each antidepressant did not reveal an increased risk for any specific malformation associated with an individual antidepressant. Table 1 lists all of the defects documented in our cohort of exposed women. There were no defects reported associated with bupropion (n = 113), escitalopram (n = 21), or trazodone (n = 17).
Discussion
To our knowledge, this is the largest prospective cohort of women (n = 928) exposed to an antidepressant during the first trimester of pregnancy, with a matched comparison group (n = 928). In this cohort, details of pregnancy outcomes, gathered prospectively and personally from each individual woman, were corroborated by the infant's physician. We did not detect an increased risk for major malformations higher than expected in the general population (that is, 1% to 3%) in the group overall, or with any individual antidepressant.
The main strength of this model is the personal interview with the individual, which includes a detailed history. Our pregnancy registry is designed specifically for collecting pregnancy outcome, consequently we are able to collect details of alcohol, tobacco, and concurrent drug use, as well as other important potential confounders of pregnancy outcome. This information is usually not possible in studies that analyze data from prescription or administrative databases, which are examples of data collection that were not designed for this purpose, but are used. Importantly, because all of the women called us early in their pregnancy, and the details of their pregnancy and drug exposure were recorded at that time, the possibility of a recall bias was eliminated. It also allows for a comparison between exposed and nonexposed groups (that is, baseline rates) of major malformations.
The major limitation of this model is most often the sample size, which is usually less than 200 women. As about 800 women are needed to rule out a 2-fold increase, we can usually only rule out a 4-to 5-fold increased risk, at best. However, in this study, by combining the antidepressants, there were 928 women, which was more than enough power to detect a 2-fold increased risk in commonly occurring malformations. In this field, it is considered a benchmark owing to the nonrandomized nature of the studies that are possible to conduct. We were not able to rule out a 2-fold increased risk of each individual antidepressant owing to the small samples sizes. However, regarding paroxetine, we were able to rule out a 2-fold increase, specifically for cardiovascular defects (1/48) as this is a relatively common defect and is known to occur in about 1 in 100 of all births. 16 As well, we were not able to rule out an increased risk of more rare malformations, as one would need thousands of cases, or alternatively conduct a case-control study, which other groups have. Another limitation is the samples are not randomly selected, as women calling a teratogenic information service do not necessarily reflect the general population. Women who participate in this type of research generally have a higher socioeconomic status and are more motivated and want to do the right things to have a healthy baby.
In summary, depression in pregnancy cannot be ignored and may require treatment with pharmacotherapy. The decision to continue or discontinue antidepressants should be made on a case-by-case basis after a careful discussion of the evidencebased information between the woman and her physician. Untreated depression during pregnancy appears to carry substantial perinatal risks, which may be direct risks to the fetus and infant, or risks secondary to unhealthy maternal behaviours arising from depression. These risks include suicidal ideation, an increased risk for miscarriages, hypertension, preeclampsia, and lower birth weight. 17 In addition, it has been documented in published studies in the peer-reviewed literature that untreated depression in pregnancy carries a 6-fold increased risk for postpartum depression. 18 We hope that the reassuring results from this study (about having a child with a relatively common major malformation) will assist women and their health care providers in making an evidence-based decision as to whether to continue antidepressant use during pregnancy.
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Résumé : Incidence des malformations majeures chez les bébés par suite d'une exposition à un antidépresseur durant la grossesse : résultats d'une vaste étude de cohortes prospective
Objectif : Déterminer si les antidépresseurs, comme groupe, accroissent le risque de malformations majeures, et évaluer chaque antidépresseur individuellement.
Méthodes : Dans le cadre du programme Motherisk, nous avons analysé les résultats des grossesses de femmes (n = 1243) exposées à des antidépresseurs durant la grossesse, à partir de cas relevés prospectivement dans notre base de données. Nous les avons ensuite comparées avec un groupe de comparaison apparié de femmes (n = 1243) qui n'ont pas été exposées (groupe non tératogène). Conclusions : L'utilisation d'antidépresseurs, comme groupe, dans le premier trimestre de la grossesse n'est pas associée à un risque accru de malformation majeure au-dessus du seuil de référence. En outre, aucun antidépresseur individuel n'était associé à un risque accru de malformation spécifique.
Résultats

